Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RLFTF (copy) Props to Alexandre below who linked a report from Relief in 2016. It was very illustrative especially about their history and their focus up to that year. Not sure it has been thoroughly discussed, but here are some of the highlights if anyone is interested that I personally found interesting.
1. They did have a CEO and other typical C-level suite guys as late as that report in 2016. Will have to do some digging to find out what happened there (if someone knows please let me know).
2. They mentioned even then their opinion is to outsource as much as they can and keep the company as "lean" as possible. They found using CRO's to do the research stuff saved money AND published research showed that CRO were on time 30% more often then doing research with in house folks. So I was wrong that how they are not ramping up and getting bigger in preparation of building off aviptadil is a sign something is amiss in the company. It seems that approach (right or wrong) is within their philosophy even back in 2016.
3. They did a phase II using aviptadil for sacroidosis and seemed to start a phase III. Tried googling the name of the phase III, but found nothing about what happened to it. Anybody know?
4. Their phase II for sarcoidosis was very interesting. It was done using an INHALED version which showed no adverse effects. So this most likely points to the INHL trial we have set up for COVID going off with no adverse effects. The study seemed not to make a difference in lung volumes in sarcoidosis based on how the results showed no change in TLC (total lung capacity) which are decreased in that disease state being a restrictive lung disease. No change in other lung parameters or gas exchange. They should have measured pulmonary pressures and right heart pressures as well to see if their was an pulmonary vasodilation and thus decrease in right sided heart strain, but oh well we can't get everything.
5. The phase II for sarcoidosis DID show once again SIGNIFICANT (75%+) decrease in inflammation via decreased TNF-alpha. This confirms nearly EVERY study to date via IV and now inhaled version it decreases inflammatory mediators. I have NO CLUE why their team didn't notice this and change direction to start trialing this for inflammatory conditions, i.e. sepsis, Inflammatory bowel disease, rheum. disease (RA, SLE, etc...).
As I have stated from the beginning this is BY FAR the most interesting aspect of this drug. It may be the "holy grail" of inflammation WITH no significant side effects via an easy route of administration (inhaled).
6. They made an agreement to offer to license aviptadil to a small, private biotech company for them to do the trials for INHL aviptadil for sarcoidosis and acute lung injury. The latter I am wondering if it went though will affect any revenue going forward for indications like that which is a precursor to ARDS by definition.
In that agreement they stated in 2018 it may also be for the RIGHTS to the patent for those indications if certain goals are met. I am assuming nothing materialized out of that agreement, but does anyone have an DD on that matter?
Maybe some of our European friends who have known the company and the biotech space in Europe will be able to flesh this part of the story out for us?
Either way that was a very interesting read on a company BEFORE they gained instant fame now due to COVID and their hopeful treatment.
$RLFTF (related) copy - Vanex Wong
taASupgoenusthsmoar i2ueoedS8 ·
From Hong Kong again. I've been reviewing immunology researches released in thr past decades and come up with an update on the qualitative side of fundamentals and valuation for VIP/RLF-100/Aviptadil/Samivir etc.
The most profitable drug throughout the past decade is Humira, a TNF-alpha inhibitor to treat inflammatory events that causes severe illness such as Arthritises (eg. Rheumatoid Arthritis ), Ankylosing Spondylitis, Ulcerative Colitis, Crohn's Disease and etc.
Humira is a drug under Abbvie, with sales of US$19.1 billion worldwide in 2019, comprising 57% of Abbvie's annual income. Abbvie's current market capitalisation is US$166.4 billion, 2020 Forward PE at 9x, EV/EBITDA at 10.4x. It's note that Humira has been facing keen competitions in immunity-regulation area and stock price peaked in 2017, with Humira's patent expiring in 2023.
Current (2020) anti-inflammatory drug market is around US$100 billion per year, including respiratory diseases caused by excess immunity reactions eg. asthma. Inhaled/ Nebulized form of RLF-100 could be a huge bomb to the anti-inflammatory drugs market for respiratory diseases.
VIP has decades of deep scientific background for its function as an anti-inflammatory regulator/ mediator working on IL-6, TNF-alpha and deactivating Chemokines (CCL-5) receptors. For RLF-100's clinical trial where 7 out of 8 were saved from ARDS, TNF-alpha level were also significantly reduced.
Although no particular clinical trials on the above illness has been done, VIP's anti-inflammatory function had been somehow proven by curing COVID-19 severe stage patients, where not the SARS-CoV-2 virus but Inflammations hurting human the most. We could expect VIP, as a naturally existing peptide having been discovered, tested and proven working for decades, would become a game changer in the anti-inflammatory field.
Meanwhile, VIP's monetisation and commercialisation process will face political and rivals obstacles due to gigantic conflict of interests, I believe the fundamental of science will work its way out.
Considered the recurring nature of commercial value as an anti-inflammatory by synthesising naturally existing VIP, my previous TP of min. $2.1 to max. $9.3 no longer holds. Revised target price to be calculated, by referrencing to anti-inflammatory peers.
Assumptions for calculation: It'll be rational to think all VIP players taking 5-10% of whole anti-inflammatory drugs market, with Relief being the biggest player, by 2025. Realisation period may go far beyond 3-5 years (look at ABBV.US). Relief Therapeutics is no longer a COIVD-19-only play.
Dedicated to Sami Said, MD, and Viktor Mutt, MD, who discovered VIP in 1970s and had a vision to see VIP commercialised decades ago.
agree ;(
$RLFTF Great Plains Health seeing success with drug treating COVID-19 http://a.msn.com/05/en-us/BB1b02B9?ocid=st
Good stuff..!!
$RLFTF Aviptadil https://www.knopnews2.com/video/2020/11/14/aviptadil/
President to give update on OWS at 4:00 Operation Warp Speed ..maybe therapeutics will be mentioned..??
Relief Therapeutics (RLFTF)
Member Level
Do you speak French?
US coronavirus: As the holidays get closer, Covid-19 hospitalizations and deaths are happening at a faster rate http://a.msn.com/01/en-us/BB1aW60b?ocid=st
soon Danielson soon
SWX: RLF
0.32 CHF +0.053 (19.85%)
Nov 11, 5:31 PM GMT+1
US sets new record for COVID-19 hospitalizations at more than 60,000 http://a.msn.com/01/en-us/BB1aTliu?ocid=st
We're still ground floor.. Illinois marijuana sales top $100 million in October https://www.stltoday.com/news/state-and-regional/illinois/illinois-marijuana-sales-top-100-million-in-october/article_d8c6a8ac-0aa3-509f-8203-8689ff181fa2.html?utm_medium=social&utm_source=twitter&utm_campaign=user-share via @stltoday
Could Texas be the next state to legalize marijuana? http://www.khou.com/article/news/politics/could-texas-be-the-next-state-to-legalize-marijuana/287-219ce153-2684-4787-bbdc-bf237837958e via @KHOU
..looking forward to being current more people will be able to buy...
Some interesting posts here today...
There will still be a great need for RLF-100! 50% or more of the population will refuse to take the vaccine and the virus may mutate making the vaccine ineffective.
- mikar
---
$RLFTF EUA Approval any day. Only covid therapy for critical patients. - andy
---
When the virus mutates, and I think it may have already? I would think that vaccines would essentially become ineffective unless you have the unmutated strain. - maston
---
Even IF this vaccine is in fact 90% effective, AND is safe, AND everyone wants it, they won't be able to produce nearly enough..."They now expect to produce up to 50 million doses, or enough to protect 25 million people this year." Next year, 2021, they think they'll be able to produce enough to protect 650 million people. So between now and the end of 2021, they would only be able to protect 10% of the world's population. Granted, they'll start in the same markets that we are targeting, but there will still be a massive need for RLF100. - veritas
---
Maybe so, but Pfizer isn’t going to be able to vaccinate the general public any time soon. - 13ryant
$RLFTF (copy) The drug's huge potential will be the out patient inhaler with the added feature of compliance and O2 sat loaded into the cloud, which can be monitored remotely. It will produce an enormous amount of data points. I t will keep people out of the hospital and reduce the need for doctor office visits. Dr. Javitts experience in bio-informatics will shepherd this into the new world of tele-medicine.
Posted By: MD VIROLOGIST
..just confirming there will be numbers to add to the trials...
The US has hit the highest daily number of new cases since the pandemic began https://www.cnn.com/2020/11/08/health/us-coronavirus-sunday/index.html
'It's a slaughter,' doctors say of new coronavirus wave
https://news.yahoo.com/coronavirus-wave-152513366.html?soc_src=hl-viewer&soc_trk=tw
FDA focused on Covid-19 ??
$RLFTF and JJ/NeuroRx are well able.. The Mirabaud analyst had said he believed that Relief would need a larger pharmaceutical company to distribute the compound in addition to its partner NeuroRx.
Of course, Relief would have to cede part of the revenues to an additional partner.
But according to Selvaraju, no large commercial organization is necessary.
RLF-100 is not a mass product, but is administered in intravenous form in hospitals. The inhalable form, for which a study will start in the coming weeks, is intended for home use.
Relief already has well-established distribution channels for both, which it can use in case of approval.
If governments in the U.S. or other countries ordered the drug, Relief would not incur any marketing or distribution costs
Dr. Javitt tweet
RLF-100 for treating COVID-19
@ResearchGate
#COVID19 community page. Read it here:
https://www.researchgate.net/publication/345245333_Rapid_Recovery_from_COVID-19_Respiratory_Failure_with_Comorbidity_in_21_Patients_Treated_with_Vasoactive_Intestinal_Peptide
https://twitter.com/Jjgmail/status/1324657796231647232?s=20
..nice little share grab while people were focusing on the election.. IMO
Lung damage found in COVID dead may shed light on 'long COVID': study https://news.yahoo.com/lung-damage-found-covid-dead-000255877.html?soc_src=hl-viewer&soc_trk=tw via @YahooNews
In 60 min. In this video we will revisit Aviptadil, also known as RLF-100, a synthetic Vasoactive Intestinal Peptide that is current undergoing clinical trials to treat COVID-19.
New data came out on Trial Site on 21 patients who received this therapy under the Emergency Use Authorization because they were so critically ill.
Interestingly, they had a 9x lower mortality than their control group. We do not have all the data published to compare these two groups, but nonetheless a very interesting finding!
We will discuss how this therapy works, the published data, and the ongoing clinical trials. Check out the video for all the details!
I was going to post that but it's for NeuroRx.. ;)
New Jersey voters just said yes to recreational marijuana. How soon until it’s available? https://www.pennlive.com/elections/2020/11/new-jersey-voters-just-said-yes-to-recreational-marijuana-now-what.html
YW :) / as mentioned earlier.. $RLFTF Nov 4th 5pm Whiteboard Doctor
"Aviptadil/RLF-100 and Covid-19: New data on treating severely ill patients"
..(copy) ..from y-h-o .. interesting thread.. ;)
Interesting post by IN
Can any of those saying "bad news leaked" tell me what the possible, probably bad news should have been at this time?
There is nothing!
- Study halt due to suspected futility? No, we wouldn't have seen 9-fold increase in survival in the open label study, unless that was a criminal enterprise
- NeuroRX wants to go public. Javitt wouldn't risk his whole livelihood by getting in on a scam that would only benefit a third party - Relief. Relief is his contract partner!
- EUA refusal? That doesn't happen like this, criteria are "safe and may be effective". We got that. Even EUA refusal wouldn't be too bad as we could soon go for full approval
- Study continues after 102 patients? Unlikely, but so what? That should have been everyone's investment base case anyway
- Study halt due to serious adverse events? JJ told us just 2 weeks ago they had treated over 165 patients nationwide and hadn't seen any. Also, drug safety is already studied for decades and safety confirmed in writing by the FDA. Also, these events wouldn't occur just when the DSMC is scheduled to meet, they come at random times. So that's a no from me.
- The pandemic magically ended the day after the election? That's still the most likely bad news I can think of, but I don't see evidence for that happening. No.
- Big players wanting to get in just before good news happen, triggering stop loss cascade? That's a YES from me. Big YES. We've seen it before on August 26.
$RLFTF 04 November 2020
RELIEF APPOINTS J. PAUL WAYMACK, M.D., SC.D. AS CONSULTANT TO STRENGTHEN MANAGEMENT TEAM
Geneva, Switzerland, November 04, 2020 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of J. Paul Waymack, M.D., Sc.D. as development and regulatory consultant. Dr. Waymack will strengthen the management team in all activities pertaining to the late stage development of RLF-100™, including regulatory activities. He will also be responsible for establishing Relief's new Clinical Advisory Board and recruiting experts to join this body, in close collaboration with Relief's Chief Medical Officer, Gilles Della Corte, M.D.
Dr. Waymack has an extensive track record in the pharmaceutical drug development arena and currently serves as President of Waymack Consulting, which provides expert services to healthcare companies. He was the founder of Kitov Pharmaceuticals and served as its Chairman of the Board of Directors as well as its Chief Medical Officer from the company's founding until his retirement in 2019. During his tenure, Kitov was granted U.S. FDA approval for its NDA for its first drug, Consensi™ (amlodipine plus celecoxib), for the simultaneous treatment of osteoarthritic pain and hypertension. Prior to founding Kitov, Dr. Waymack was a U.S. FDA medical officer, an associate professor of surgery and director of the surgical intensive care unit at the New Jersey School of Medicine and Dentistry. He was also formerly chief of surgical studies at the U.S. Army’s Institute for Surgical Research. Dr. Waymack has been granted multiple patents and has authored or co-authored over 100 publications. He currently sits on multiple boards of directors and advisory boards for companies within the pharmaceutical industry. He received his medical degree from the Virginia Commonwealth University School of Medicine.
Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, said: “I am thrilled to have Paul join us on our journey to see RLF-100™ through clinical development and reach those COVID-19 patients who so desperately need new therapeutic options. His extensive experience in drug development and intimate understanding of the workings of the FDA will be invaluable to Relief."
“Relief's team is in the midst of an exciting time as they work diligently to advance RLF-100™ through late stage development at a pace unprecedented in the field. I am delighted to join and support them in the final stages of development for this promising drug candidate and hopefully through regulatory approval,” commented J. Paul Waymack, M.D., Sc.D., Consultant for Relief.
0.28 Making it's way back up from .19 SWX:RLF
SWX: RLF
0.28 CHF -0.075 (21.43%)
From Ya-h-o 5hrs ago
Coz 5 hours ago
Thank you for your email.
We understand that it is difficult to sort through the various news sources to find the truth.
As we have reported, our Phase 2b/3 trial passed the first interim analysis (which included an unblinded futility assessment) with positive results and a second interim analysis is slated to occur imminently, involving roughly two-thirds of the target number of patients to be enrolled (i.e., 102 out of a total 165 subjects).
Furthermore, we have released data with our partner NeuroRx Inc. from the Expanded Access Program (EAP) with RLF-100 showing very intriguing clinical efficacy data in extremely critically ill COVID-19 patients (i.e., those with no other treatment options, who have been on ventilators or ECMO for extended periods of time) in whom none of the existing approved or experimental drugs have been shown to work at all.
This gives us substantial confidence in the outcome of our ongoing Phase 2b/3 trial with the IV formulation of the drug.
As soon as we have new information from the trial, we will share it with the market and all stakeholders promptly.
We wish you and your loved ones continued health.
Kind regards,
Brittney Sojeva
Marijuana legalization measures pass in 4 states https://www.yahoo.com/gma/marijuana-legalization-measures-pass-3-044900012.html?soc_src=social-sh&soc_trk=tw via @GMA
Marijuana legalization measures pass in 4 states https://www.yahoo.com/gma/marijuana-legalization-measures-pass-3-044900012.html?soc_src=social-sh&soc_trk=tw via @GMA
These States Passed Provisions To Legalize Marijuana In The 2020 Election via @forbes https://www.forbes.com/sites/advisor/2020/11/04/these-states-passed-provisions-to-legalize-marijuana-in-the-2020-election/
These States Passed Provisions To Legalize Marijuana In The 2020 Election via @forbes https://www.forbes.com/sites/advisor/2020/11/04/these-states-passed-provisions-to-legalize-marijuana-in-the-2020-election/
New Jersey voters legalize recreational marijuana http://a.msn.com/01/en-us/BB1aGr0r?ocid=st
New Jersey voters legalize recreational marijuana http://a.msn.com/01/en-us/BB1aGr0r?ocid=st
Share Grab..